Satsuma Pharmaceuticals, Inc. Retained Earnings
Satsuma Pharmaceuticals, Inc. had Retained Earnings of -$222.09 million as of 2023-03-31, per its 10-Q filed 2023-05-11.
Discontinued › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2023-05-11
- 2023-03-31: Retained Earnings (Accumulated Deficit) -$222.09M.
- 2022-12-31: Retained Earnings (Accumulated Deficit) -$211.79M.
- 2022-09-30: Retained Earnings (Accumulated Deficit) -$188.66M.
- 2022-06-30: Retained Earnings (Accumulated Deficit) -$173.52M.
| Period end | Retained Earnings (Accumulated Deficit) |
|---|---|
| 2023-03-31 | -$222.09M 10-Q · filed 2023-05-11 |
| 2022-12-31 | -$211.79M 10-Q · filed 2023-05-11 |
| 2022-09-30 | -$188.66M 10-Q · filed 2022-11-03 |
| 2022-06-30 | -$173.52M 10-Q · filed 2022-08-09 |
| 2022-03-31 | -$157.25M 10-Q · filed 2022-05-10 |
| 2021-12-31 | -$141.74M 10-K · filed 2023-03-28 |
| 2021-09-30 | -$126.19M 10-Q · filed 2021-11-09 |
| 2021-06-30 | -$112.85M 10-Q · filed 2021-08-10 |
| 2021-03-31 | -$101.02M 10-Q · filed 2021-05-11 |
| 2020-12-31 | -$90.56M 10-K · filed 2022-03-15 |
| 2020-09-30 | -$78.09M 10-Q · filed 2020-11-10 |
| 2020-06-30 | -$66.04M 10-Q · filed 2020-08-11 |
| 2020-03-31 | -$54.77M 10-Q · filed 2020-05-12 |
| 2019-12-31 | -$43.00M 10-K · filed 2021-03-25 |
| 2019-09-30 | -$32.19M 10-Q · filed 2019-11-12 |
| 2018-12-31 | -$14.83M 10-K · filed 2020-03-10 |